The present disclosure provides an anti-inflammatory formulation comprising a homogenized mixture of at least one potentised cytokines selected from the group consisting of IL la (interleukin 1-alpha), IL lb (interleukin 1-beta), IL 2, IL 4, IL 5, IL 6, TNF-a (Tumor Necrosis Factor-alpha), INF-y, IL 12, IL 13, IL 17, IL 20 and IL 23.